Display options
Cite
Poordad F, Lawitz E, Gutierrez JA, et al. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017;5(4):371-375doi: 10.1002/ccr3.841.
Poordad, F., Lawitz, E., Gutierrez, J. A., Guerrero, J., Speeg, K., & Swenson, E. S. (2017). An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clinical case reports, 5(4), 371-375. https://doi.org/10.1002/ccr3.841
Poordad, Fred, et al. "An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin." Clinical case reports vol. 5,4 (2017): 371-375. doi: https://doi.org/10.1002/ccr3.841
Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES. An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr. PMID: 28396749; PMCID: PMC5378822.
Copy Download .nbib Format: NLM
Share it on

Clin Case Rep. 2017 Feb 03;5(4):371-375. doi: 10.1002/ccr3.841. eCollection 2017 Apr.

An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin.

Clinical case reports

Fred Poordad, Eric Lawitz, Julio A Gutierrez, Juan Guerrero, Kermit Speeg, Eugene S Swenson

Affiliations

  1. Texas Liver Institute San Antonio Texas USA; Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
  2. Department of Transplant Hepatology University of Texas Health Science San Antonio Texas USA.
  3. Bristol-Myers Squibb Research and Development Wallingford Connecticut USA.

PMID: 28396749 PMCID: PMC5378822 DOI: 10.1002/ccr3.841

Abstract

This case suggests that initiation of HCV therapy immediately after liver transplantation with well-tolerated, all-oral regimens may achieve a virologic cure in HCV-positive recipients, thus preventing post-transplant HCV recurrence and associated disease progression. This strategy may broaden utilization of HCV-positive donor livers, potentially including HCV-negative transplant recipients.

Keywords: Daclatasvir; hepatitis C; liver transplantation; sofosbuvir

References

  1. Clin Pharmacokinet. 2015 Jul;54(7):677-90 - PubMed
  2. Transpl Int. 2015 Aug;28(8):980-9 - PubMed
  3. J Hepatol. 2012 Sep;57(3):675-88 - PubMed
  4. Liver Transpl. 2015 Oct;21(10):1327-9 - PubMed
  5. Am J Transplant. 2015 Jan;15 Suppl 2:1-28 - PubMed
  6. Hepatology. 2002 Nov;36(5 Suppl 1):S30-4 - PubMed
  7. Liver Transpl. 2003 Nov;9(11):S28-34 - PubMed
  8. Liver Int. 2015 Jan;35(1):1-4 - PubMed
  9. Gastroenterology. 2012 May;142(6):1373-1383.e1 - PubMed
  10. N Engl J Med. 2014 Dec 18;371(25):2375-82 - PubMed
  11. Am J Transplant. 2014 Jan;14 Suppl 1:69-96 - PubMed
  12. Liver Transpl. 2015 Jun;21(6):823-30 - PubMed
  13. Hepatology. 2016 May;63(5):1493-505 - PubMed
  14. Ann Transplant. 2015 Jan 22;20:44-50 - PubMed
  15. Clin Drug Investig. 2015 May;35(5):281-9 - PubMed
  16. Ann Pharmacother. 2015 Jun;49(6):674-87 - PubMed
  17. Lancet. 1995 Feb 25;345(8948):484-7 - PubMed
  18. Liver Transpl. 2015 Apr;21(4):423-34 - PubMed
  19. Gastroenterology. 2015 Jan;148(1):100-107.e1 - PubMed
  20. Gastroenterology. 2015 Sep;149(3):649-59 - PubMed
  21. Liver Transpl. 2011 May;17 (5):528-38 - PubMed

Publication Types

Grant support